AA
NTLA icon

Advisory Alpha’s Intellia Therapeutics NTLA Stock Holding History

Advisory Alpha’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-100
Closed -$2K – 465
2020
Q3 		$2K Buy
+100
New +$2.08K ﹤0.01% 613
2020
Q2 		– Sell
-100
Closed -$1.42K – 427
2020
Q1 		$1.42K Hold
100
– – ﹤0.01% 619
2019
Q4 		$1.39K Hold
100
– – ﹤0.01% 677
2019
Q3 		$1.04K Buy
+100
New +$1.59K ﹤0.01% 732
2019
Q2 		– Sell
-100
Closed -$1.62K – 462
2019
Q1 		$1.62K Buy
+100
New +$1.49K ﹤0.01% 564

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AVAX
Atlas Venture Associates XI Cambridge, Massachusetts $631M AUM

Advisory Alpha's NTLA Position: Q4 2020 in Review

Advisory Alpha sold out of Intellia Therapeutics (NTLA) in Q4 2020, closing a stake of 100 shares — an estimated $2K sold.

Advisory Alpha first reported a position in NTLA in Q1 2019 and held it in 5 quarters. The position peaked at $2K in Q3 2020. 240 funds tracked by Wall St. Rank hold NTLA as of Q4 2020.

  • Advisory Alpha reported no remaining Intellia Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Advisory Alpha sold 100 Intellia Therapeutics shares in Q4 2020, an estimated $2K.
  • Advisory Alpha first reported a position in Intellia Therapeutics in Q1 2019 and held it in 5 quarters.
  • Advisory Alpha's Intellia Therapeutics position peaked at $2K in Q3 2020.
  • 240 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2020.

Based on Advisory Alpha's 13F filing for Q4 2020, filed 16 Feb 2021.